CoChat

AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models

Open access
Vasireddy, Vidyullatha, Mills, Jason A., Gaddameedi, Rajashekhar, Basner-Tschakarjan, Etiena, Kohnke, Monika, Black, Aaron D., Alexandrov, Krill, Zhou, Shangzhen, Maguire, Albert M., Chung, Daniel C., Mac, Helen, Sullivan, Lisa, Gadue, Paul, Bennicelli, Jeannette L., French, Deborah L., Bennett, Jean · 2013 · PLoS ONE
Cited by 79

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Choroideremia (CHM) is an X- linked retinal degeneration that is symptomatic in the 1(st) or 2(nd) decade of life causing nyctalopia and loss of peripheral vision. The disease progresses through mid-life, when most patients become blind. CHM is a favorable target for gene augmentation therapy, as the disease is due to loss of function of a protein necessary for retinal cell health, Rab Escort Protein 1 (REP1).The CHM cDNA can be packaged in recombinant adeno-associated virus (rAAV), which has an established track record in human gene therapy studies, and, in addition, there are sensitive and quantitative assays to document REP1 activity. An animal model that accurately reflects the human condition is not available. In this study, we tested the ability to restore REP1 function in personalized in vitro models of CHM: lymphoblasts and induced pluripotent stems cells (iPSCs) from human patients. The initial step of evaluating safety of the treatment was carried out by evaluating for acute retinal histopathologic effects in normal-sighted mice and no obvious toxicity was identified. Delivery of the CHM cDNA to affected cells restores REP1 enzymatic activity and also restores proper protein trafficking. The gene transfer is efficient and the preliminary safety data are encouraging. These studies pave the way for a human clinical trial of gene therapy for CHM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0061396

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 44

  1. IM MacDonald, 2009, Choroideremia: new findings from ocular pathology and review of recent literature, Surv Ophthalmol, 54, 401, 10.1016/j.survophthal.2009.02.008 · DOI
  2. EV Rafuse, 1968, Choroideremia. A pathological report, Can J Ophthalmol, 3, 347
  3. RG Coussa, 2012, Choroideremia: effect of age on visual acuity in patients and female carriers, Ophthalmic Genet, 33, 66, 10.3109/13816810.2011.623261 · DOI
  4. RG Coussa, 2012, Choroideremia: a review of general findings and pathogenesis, Ophthalmic Genet, 33, 57, 10.3109/13816810.2011.620056 · DOI · Paper page
  5. MC Seabra, 1996, New insights into the pathogenesis of choroideremia: a tale of two REPs, Ophthalmic Genet, 17, 43, 10.3109/13816819609057869 · DOI
  6. JA van den Hurk, 1997, Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene, Hum Mutat, 9, 110, 10.1002/(SICI)1098-1004(1997)9:2<110::AID-HUMU2>3.0.CO;2-D · DOI · Paper page
  7. JG Flannery, 1990, A histopathologic study of a choroideremia carrier, Invest Ophthalmol Vis Sci, 31, 229
  8. HJ Perez-Cano, 2009, CHM gene molecular analysis and X-chromosome inactivation pattern determination in two families with choroideremia, Am J Med Genet A, 149A, 2134, 10.1002/ajmg.a.32727 · DOI
  9. S Pfeffer, 2004, Targeting Rab GTPases to distinct membrane compartments, Nat Rev Mol Cell Biol, 5, 886, 10.1038/nrm1500 · DOI · Paper page
  10. FL Zhang, 1996, Protein prenylation: molecular mechanisms and functional consequences, Annu Rev Biochem, 65, 241, 10.1146/annurev.bi.65.070196.001325 · DOI · Paper page
  11. K Alexandrov, 1994, Rab escort protein-1 is a multifunctional protein that accompanies newly prenylated rab proteins to their target membranes, EMBO Journal, 13, 5262, 10.1002/j.1460-2075.1994.tb06860.x · DOI · Paper page
  12. A Rak, 2004, Structure of the Rab7:REP-1 complex: insights into the mechanism of Rab prenylation and choroideremia disease, Cell, 117, 749, 10.1016/j.cell.2004.05.017 · DOI · Paper page
  13. YV Sergeev, 2009, The functional effect of pathogenic mutations in Rab escort protein 1, Mutat Res, 665, 44, 10.1016/j.mrfmmm.2009.02.015 · DOI · Paper page
  14. NV Strunnikova, 2009, Loss-of-function mutations in Rab escort protein 1 (REP-1) affect intracellular transport in fibroblasts and monocytes of choroideremia patients, PLoS One, 4, e8402, 10.1371/journal.pone.0008402 · DOI · Paper page
  15. MC Seabra, 1995, Deficient geranylgeranylation of Ram/Rab27 in choroideremia, J Biol Chem, 270, 24420, 10.1074/jbc.270.41.24420 · DOI · Paper page
  16. FP Cremers, 1994, REP-2, a Rab escort protein encoded by the choroideremia-like gene, J Biol Chem, 269, 2111, 10.1016/S0021-9258(17)42142-9 · DOI · Paper page
  17. FPM Cremers, 1992, An autosomal homologue of the choroideremia gene colocalizes with the Usher syndrome type II locus on the distal part of chromosome 1q, Hum Mol Genet, 1, 71, 10.1093/hmg/1.2.71 · DOI · Paper page
  18. H van Bokhoven, 1994, Mutation spectrum in the CHM gene of Danish and Swedish choroideremia patients, Hum Mol Genet, 3, 1047, 10.1093/hmg/3.7.1047 · doi:10.1093/hmg/3.7.1047
  19. E-M Sankila, 1992, Aberrant splicing of the CHM gene is a significant cause of choroideremia, Nature Genetics, 1, 109, 10.1038/ng0592-109 · DOI
  20. FRM Cremers, 1990, Deletions in patients with classical choroideremia vary in size from 45 kb to several megabases, American Journal of Human Genetics, 47, 622
  21. N Keiser, 2005, Spatial and temporal expression patterns of the choroideremia gene in the mouse retina, Mol Vis, 11, 1052
  22. Lipinski DM, Thake M, Maclaren RE (2012) Clinical applications of retinal gene therapy. Prog Retin Eye Res. · DOI
  23. J Bennett, 2012, AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness, Sci Transl Med, 4, 120ra115, 10.1126/scitranslmed.3002865 · DOI · Paper page
  24. RW Herzog, 1999, Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy, Thromb Haemost, 82, 540, 10.1055/s-0037-1615877 · DOI
  25. D Grimm, 2003, Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy, Blood, 102, 2412, 10.1182/blood-2003-02-0495 · DOI · Paper page
  26. P Forsythe, 1997, A carboxy-terminal truncation of 99 amino acids resulting from a novel mutation (Arg555-> stop) in the CHM gene leads to Choroideremia, Experimental Eye Research, 64, 487, 10.1006/exer.1996.0200 · doi:10.1006/exer.1996.0200
  27. V Vasireddy, 2011, Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation, PLoS One, 6, e21193, 10.1371/journal.pone.0021193 · DOI
  28. V Anand, 2003, Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus, Vision Res, 43, 919, 10.1016/S0042-6989(02)00389-9 · DOI
  29. JM Polo, 2010, When fibroblasts MET iPSCs, Cell Stem Cell, 7, 5, 10.1016/j.stem.2010.05.018 · DOI
  30. JM Polo, 2010, Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells, Nat Biotechnol, 28, 848, 10.1038/nbt.1667 · DOI · Paper page
  31. PH Lerou, 2008, Derivation and maintenance of human embryonic stem cells from poor-quality in vitro fertilization embryos, Nat Protoc, 3, 923, 10.1038/nprot.2008.60 · DOI
  32. PH Lerou, 2008, Human embryonic stem cell derivation from poor-quality embryos, Nat Biotechnol, 26, 212, 10.1038/nbt1378 · DOI
  33. K Kim, 2010, Epigenetic memory in induced pluripotent stem cells, Nature, 467, 285, 10.1038/nature09342 · DOI · Paper page
  34. MC Seabra, 1992, Purification of component A of Rab geranylgeranyl transferase: Possible identity with the choroideremia gene product, Cell, 70, 1049, 10.1016/0092-8674(92)90253-9 · DOI · Paper page
  35. Basiji DA, Ortyn WE, Liang L, Venkatachalam V, Morrissey P (2007) Cellular image analysis and imaging by flow cytometry. Clin Lab Med 27: 653–670, viii. · DOI · Paper page
  36. KE McGrath, 2008, Multispectral imaging of hematopoietic cells: where flow meets morphology, J Immunol Methods, 336, 91, 10.1016/j.jim.2008.04.012 · DOI
  37. T Tolmachova, 2006, Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia, J Clin Invest, 116, 386, 10.1172/JCI26617 · DOI · Paper page
  38. T Tolmachova, 2012, CHM/REP1 cDNA delivery by lentiviral vectors provides functional expression of the transgene in the retinal pigment epithelium of choroideremia mice, J Gene Med, 14, 158, 10.1002/jgm.1652 · DOI · Paper page
  39. JS Meyer, 2009, Modeling early retinal development with human embryonic and induced pluripotent stem cells, Proc Natl Acad Sci U S A, 106, 16698, 10.1073/pnas.0905245106 · DOI · Paper page
  40. MJ Phillips, 2012, Blood-derived human iPS cells generate optic vesicle-like structures with the capacity to form retinal laminae and develop synapses, Invest Ophthalmol Vis Sci, 53, 2007, 10.1167/iovs.11-9313 · DOI · Paper page
  41. O Pylypenko, 2003, Structure of Rab escort protein-1 in complex with Rab geranylgeranyltransferase, Mol Cell, 11, 483, 10.1016/S1097-2765(03)00044-3 · DOI
  42. LM Hoffman, 1997, Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery, Invest Ophthalmol Vis Sci, 38, 2224
  43. SE Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol Genet Metab, 80, 148, 10.1016/j.ymgme.2003.08.016 · DOI · Paper page
  44. F Simonelli, 2010, Gene Therapy for Leber’s Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration, Mol Ther, 18, 643, 10.1038/mt.2009.277 · DOI · Paper page

Cited by

See all 79

Metadata

Authors
Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J. L., French, D. L., & Bennett, J.
Venue
PLoS ONE
Published
2013-05-07
Volume
8
Issue
5
Pages
e61396
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2117381269
Cited by
79
References
7
FWCI
4.57
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. https://app.cochat.ai/papers/10.1371/journal.pone.0061396
The paper
Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J. L., French, D. L., & Bennett, J. (2013). AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. PLoS ONE. https://doi.org/10.1371/journal.pone.0061396

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.